After intentionally slowing its inorganic ambitions for practically three years to soak up its greatest acquisition, Dr Lal PathLabs is as soon as once more scanning the marketplace for offers — this time with a transparent deal with plugging gaps in South India.

The nation’s largest diagnostics chain acquired Mumbai-based Suburban Diagnostics in August 2021 in a Rs 925-crore transaction, a deal that considerably strengthened its presence in western India but in addition demanded administration bandwidth. “Now we have not completed acquisitions just lately as a result of the Suburban integration itself took important bandwidth. That’s now largely stabilised,” Ved Goel, group chief monetary officer and chief government officer, worldwide enterprise, at Dr Lal PathLabs, advised Enterprise Normal.

With integration largely behind it, the corporate believes the stage is about for selective acquisitions. Nevertheless, Goel is evident that Dr Lal won’t chase offers merely to spice up topline. “I don’t need to do M&A simply so as to add turnover. Any acquisition should match strategically. If an area will take too lengthy to scale organically, then M&A is sensible — because it did for the Mumbai market,” he stated.

South India stays the obvious white house. Not like the north, the southern market is fragmented throughout a number of states with distinct aggressive dynamics. “South is unquestionably a niche space for us. It isn’t one homogeneous market — Tamil Nadu, Kerala, Telangana, Karnataka are all very completely different,” Goel stated. Whereas Dr Lal has constructed sturdy clusters in Kerala and has a sizeable presence in Bengaluru — the place it’s probably the second-largest participant — it lacks a single platform that may ship significant scale throughout the area. Future acquisitions, if any, are more likely to be smaller, focused and geography-specific.

This renewed inorganic curiosity comes at the same time as Dr Lal sharpens execution in its core markets. Delhi NCR, lengthy thought-about a mature geography, has emerged as a shock development engine. “After a few years, Delhi NCR has began rising in double digits,” Goel stated. The revival has been pushed by recent investments — new labs and assortment centres, sooner turnaround instances, and a technology-led revamp of older infrastructure. Routine studies are actually delivered inside two to 6 hours, considerably enhancing buyer expertise. “This has pushed development in a longtime market,” he added.

Operationally, the corporate has additionally benefited from enhancing realisations regardless of muted affected person development within the December quarter. Exams per affected person rose about 5 per cent year-on-year as clients more and more opted for wellness and preventive packages quite than standalone exams. A richer combine of specialized and high-end testing — notably in oncology and genomics — and geographic diversification additionally aided margins.

Radiology, in the meantime, is rising as a measured development lever. Dr Lal started its imaging pilot practically two years in the past with a single centre and now operates three, with one other within the pipeline, largely targeted on Delhi. Growth is calibrated. “Radiology isn’t tremendous quick. The problem isn’t capex, it’s discovering radiologists,” Goel stated, pointing to expertise shortage and regulatory constraints. Analysts see radiology as a gradual, margin-accretive possibility quite than a speedy scale-up alternative.

BNP Paribas analysts, in a current be aware, stated Dr Lal’s December-quarter efficiency underscored the advantages of its volume-led technique. Whereas affected person development lagged business expectations, realisations stunned positively resulting from higher take a look at combine and better exams per affected person quite than worth hikes. Additionally they flagged Delhi NCR’s double-digit rebound as proof that infrastructure investments are starting to repay, even on a big base.

Trade-wide, diagnostics development is stabilising quite than slowing, pushed by preventive healthcare, rising power illnesses and increasing hospital infrastructure into tier-2 cities. Goel believes 9–10 per cent development is now the baseline, with organised gamers like Dr Lal effectively positioned to consolidate share as they soak up inflation higher than unorganised labs.

For Dr Lal, that mixture of operational momentum and renewed balance-sheet capability is now reopening the acquisition playbook — rigorously, and with the South firmly in focus.